Titan Telecoms rapidly expands network across Australia with Adtran
Adtran today announced that Titan Telecoms has deployed its FSP 3000 open line system (OLS) with flexgrid ROADMs, and its FSP 3000 TeraFlex™ open terminal to create a high-capacity, ultra-flexible optical backbone network. The new solution empowers Titan Telecoms to expand across Australia, offering next-generation backhaul at high speed and high capacity between data centers. The infrastructure supports speeds up to 800Gbit/s across the backbone, with customer-facing interfaces up to 400Gbit/s. Utilizing Adtran Ensemble software for network and service management, and leveraging the Adtran ALM proactive fiber monitoring solution, the solution also enables Titan Telecoms to ensure the highest levels of service availability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230706706325/en/
Adtran’s intelligent open networking technology is helping Titan Telecoms to scale its infrastructure at speed. (Photo: Business Wire)
“Our new network is great news for Australian businesses and service providers. It empowers us to expand quickly into new areas and reach more locations than ever before. With Adtran’s technology supporting rapid service rollout, we can help our customers stay ahead of the curve in today’s fast-changing digital landscape,” said Matt McDonough, CEO of Titan Telecoms. “This deployment also lets our customers harness new levels of automation and control. Now we can deliver a unified and comprehensive view of all services and resources, creating a seamless and easy-to-use management experience.”
Titan Telecoms’ new infrastructure is built on Adtran’s FSP 3000 open optical transport technology, including the FSP 3000 TeraFlex™. Using software-defined fractional QAM modulation and adaptive baud rate capabilities, this flexible terminal boosts capacity and ensures the lowest cost for every fiber path. The solution also offers advanced streaming telemetry, which enables Titan Telecoms to provide its customers with real-time performance data and helps enhance quality of service for end users. In addition to this, the network features the Adtran ALM fiber monitoring platform. This simple plug-and-play assurance device enables proactive maintenance, shortening repair cycles and reducing unnecessary site visits. What’s more, with Adtran’s Ensemble software providing intelligent automation capabilities, Titan Telecoms is able to streamline and accelerate service delivery.
“We’re helping Titan Telecoms execute its ambitious plans to reach more areas and provide its customers with even more value. The new infrastructure significantly boosts capacity and guarantees maximum data throughput over every link. It delivers high-performance services with efficiency, reliability and flexibility. This will give Australian businesses and carriers the foundation they need to succeed both now and in the future,” commented Erik Lindberg, GM of APAC sales at Adtran. “Our ALM is also a key component of the new solution. It offers continuous in-service fiber monitoring, allowing Titan Telecoms to locate fiber degradation and take targeted action before any services are affected.”
About Titan Telecoms
Titan Telecoms, an innovative Australian provider specializing in cutting-edge dark fibre and wavelength solutions, is revolutionizing the telecommunications landscape. By bridging the backhaul infrastructure gap, Titan Telecoms delivers high-bandwidth connections for businesses and individuals nationwide. With advanced next-generation backhaul solutions, Titan Telecoms meets the growing demand for reliable, high-bandwidth connectivity. They cater to domestic and foreign carriers, small ISPs, wireless providers, and businesses seeking dependable high-bandwidth connectivity across Australia. Find more at Titan Telecoms and LinkedIn.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230706706325/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release
The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom